Treatments in depression

Dialogues in Clinical Neuroscience

Volumn 8, Issue 2, 2006, Pages 191-206

  Duval, Fabrice ^a,c   Lebowitz, Barry D ^b   Macher, Jean Paul ^a  

^a Centre Hospitalier de Rouffach   (France)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NONE   (France)

Author keywords

Antidepressants; Kindling; Major depression; Management strategy; Neuroplasticity; Treatment predictor

Indexed keywords

AGOMELATINE; AMFEBUTAMONE; AMITRIPTYLINE; AMOXAPINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DOPAMINE UPTAKE INHIBITOR; DOXEPIN; FLUOXETINE; FLUVOXAMINE; HISTAMINE H1 RECEPTOR ANTAGONIST; IMIPRAMINE; IPRONIAZID; MIANSERIN; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; MOOD STABILIZER; NORADRENALIN UPTAKE INHIBITOR; REBOTEXINE; SELEGILINE; SEROTONIN ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TIANEPTINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE;

AGITATION; AGRANULOCYTOSIS; ANOREXIA; ANXIETY; BLURRED VISION; CIRCADIAN RHYTHM; CONCENTRATION LOSS; CONFUSION; CONSTIPATION; DEPRESSION; DIARRHEA; DRUG SELECTIVITY; GENETIC VARIABILITY; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMAGING SYSTEM; INSOMNIA; NAUSEA; POLYSOMNOGRAPHY; REVIEW; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP PARAMETERS; STRESS; TREATMENT RESPONSE; XEROSTOMIA;

ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSION; HUMANS; MODELS, BIOLOGICAL;

EID: 33746354295     PISSN: 12948322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (147)

1. Kessler RC, Berglund P, Demler O, et al. National Comorbidity Survey Replication. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289:3095-3105.
2. Frank E, Novik D, Kupfer DJ. Antidepressants and psychotherapy: a clinical research review. Dialogues Clin Neurosci. 2005;7:263-272.
3. Prien RF, Kocsis JH. Long-term treatment of mood disorders. In: Bloom FE; Kupfer DJ, eds. Psychopharmacology: the Fourth Generation Of Progress. New York, NY: Raven Press; 1995:1067-1079.
4. Kupfer DJ. The pharmacological management of depression. Dialogues Clin Neurosci. 2005;7:191-205.
5. Trivedi MH, Rush AJ, Wisniewski SR, et al, STAR*D Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163:28-40.
6. Kelller MB, Hirschfeld RM, Hanks D. Double depression: a distintive sub-type of unipolar depression. J Affect Disord. 1997;45:65-73.
7. Zarate CA, Tohen M, Land M, Cavanagh S. Functional impairment and cognition in bipolar disorder. Psychiatry Q. 2000;71:309-329.
8. American Psychiatric Association. Practice Guidelines for Patients With Major Depressive Disorder. 2nd ed. Washington, DC: American Psychiatric Association; 2000.
9. Dilsaver SC, Chen YW, Swann AC, Shoaib AM, Krajewski KJ. Suicidality in patients with pure and depressive mania. Am J Psychiatry. 1994;151:1312-1315.
10. Kapur S, Mieczkowski T, Mann JJ. Antidepressant medications and the relative risk of suicide attempt and suicide. JAMA. 1992;26:3441-3445.
11. Isometsa ET, Henriksson MM, Aro HM, Heikkinen ME, Kuoppasalmi KI, Lonnqvist JK. Suicide in major depression. Am J Psychiatry. 1994;151:530-536.
12. Schulz P, Macher JP. The clinical pharmacology of depressive states. Dialogues Clin Neuroci. 2002;4:47-56.
13. Elkin I, Shea MT, Watkins JT, et al. National Institute of Mental Health Treatment of Depression Collaborative Research Program. General effectiveness of treatments. Arch Gen Psychiatry. 1989;46:971-982.
14. Moller HJ, Fuger J, Kasper S. Efficacy of new generation antidepressants: meta-analysis of imipramine-controlled studies. Pharmacopsychiatry. 1994;27:215-223.
15. Tedlow J, Fava M, Uebelacker L, Nierenberg AA, Alpert JE, Rosenbaum J. Outcome definitions and predictors in depression. Psychother Psychosom. 1998;67:266-270.
16. Spiker DG, Weiss JC, Dealy RS, et al. The pharmacological treatment of delusional depression. Am J Psychiatry. 1985;142:430-436.
17. Wijkstra J, Lijmer J, Balk FJ, Geddes JR, Nolen WA. Pharmacological treatment for unipolar psychotic depression: systematic review and meta-analysis. Br J Psychiatry. 2006;188:410-415.
18. Dannon PN, Lowengrub K, Gonopolski Y, Kotler M. Current and emerging somatic treatment strategies in psychotic major depression. Expert Rev Neurother. 2006;6:73-80.
19. Thase ME, Sachs GS. Bipolar depression: pharmacotherapy and related therapeutic strategies. Biol Psychiatry. 2000;48:558-572.
20. Peet M. Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants. Br J Psychiatry. 1994;164:549-550.
21. Visser HM, Van Der Mast RC. Bipolar disorder, antidepressants and induction of hypomania or mania. A systematic review. World J Biol Psychiatry. 2005;6:231-241.
22. Yatham LN, Goldstein JM, Vieta E, et al. Atypical antipsychotics in bipolar depression: potential mechanisms of action. J Clin Psychiatry. 2005;66 (suppl 5):40-48.
23. Hatzinger M. Neuropeptides and the hypothalamic-pituitary-adrenocortical (HPA) system: review of recent research strategies in depression. World J Biol Psychiatry. 2000;1:105-111.
24. Carroll BJ, Feinberg M, Greden JF, et al. A specific laboratory test for the diagnosis of melancholia: standardisation, validation, and clinical utility. Arch Gen Psychiatry. 1981;38:15-22.
25. APA Task Force On Laboratory Tests. The dexamethasone suppression test: an overview of its current status in psychiatry. Am J Psychiatry. 1987;14:1253-1262.
26. Nelson JC, Davis JM. DST studies in psychotic depression: a meta-analysis. Am J Psychiatry. 1997;154:1497-1503.
27. Heuser I, Yassouridis A, Holsboer F. The combined dexamethasone/CRH test: a refined laboratory test for psychiatric disorders. J Psychiatr Res. 1994;28:341-356.
28. Ansseau M, Papart P, Pitchot W, Timsit-Berthier M, Legros JJ, von Frenckell R. Dexamethasone suppression test and the prediction of treatment response to selective antidepressants. Eur Psychiatry. 1992;7:191-194.
29. Greden JF, Gardner R, King D, Grunhaus L, Carrol BJ, Kronfol, Z. Dexamethasone suppression tests in antidepressant treatment of melancholia. Arch Gen Psychiatry. 1983;40:493-500,
30. Peselow ED, Stanley M, Filippi AM, Barouche F, Goodnick P, Fieve R. The predictive value of the dexamethasone suppression test: a placebo-controlled study. Br J Psychiatry. 1989;155:667-672.
31. Holsboer-Trachsler E, Stohler R, Hatzinger M. Repeated administration of the combined dexamethasone-human corticotropin releasing hormone stimulation test during treatment of depression. Psychiatry Res. 1991;38:163-171.
32. Duval F, Macher JP, Mokrani MC. Difference between evening and morning thyrotropin response to protirelin in major depressive episode. Arch Gen Psychiatry. 1990;47:443-448.
33. Mokrani MC, Duval F, Monreal J, Champeval C, Maurice D, Macher JP. Chronobiological HPT axis dysfunction in depression. In: New Research Abstracts. 159th Meeting, American Psychiatric Association, Toronto, Canada: APA; 2006.
34. Loosen PT, Prange AJ. Serum thyrotropin response to thyrotropin-releasing hormone in psychiatric patients: a review. Am J Psychiatry. 1982; 139:405-416.
35. Whybrow PC, Bauer MS. Effects of peripheral thyroid hormones on the central nervous system: relevance to disorders of mood. Current Topics Neuroendocrinology. 1988;8:309-327.
36. Duval F, Mokrani MC, Crocq MA, Bailey P, Macher JP. Influence of thyroid hormones on morning and evening TSH response to TRH in major depression. Biol Psychiatry. 1994;35:926-934.
37. Calloway SP, Dolan RJ, Fonagy P, De Souza VF, Wakeling A. Endocrine changes and clinical profiles in depression: II. The thyrotropin-releasing hormone test. Psychol Med. 1984;14:759-765.
38. Kirkegaard C, Faber J. Influence of free thyroid hormone levels on the TSH response to TRH in endogenous depression. Psychoneuroendocrinology. 1986;11:491-497.
39. Duval F, Mokrani MC, Crocq MA, et al. Effect of antidepressant medication on morning and evening thyroid function tests during a major depressive episode. Arch Gen Psychiatry. 1996;53:833-840.
40. Siever LJ, Davis KL. Overview: toward a dysregulation hypothesis of depression. Am J Psychiatry. 1985;142:1017-1031.
41. Abelson JL, Glitz D, Cameron OG, et al. Blunted growth hormone response to clonidine in patients with generalized anxiety disorder. Arch Gen Psychiatry. 1991;48:157-162.
42. Uhde TW, Stein MB, Vittone BJ, et al. Behavioral and physiolologic effect of short-term and long-term administration of clonidine in panic disorder. Arch Gen Psychiatry. 1989;46:170-177.
43. Brambilla F, Perna G, Garberi, et al. A2-adrenergic receptor sensitivity in panic disorder: I. GH response to GHRH and clonidine stimulation in panic disorder. Psychoneuroendocrinology. 1995;20:1-9.
44. Tancer ME, Stein MB, Uhde TW. Growth hormone response to intravenous clonidine in social phobia: comparison to patients with panic disorder and healthy volunteers. Biol Psychiatry. 1993;34:591-595.
45. Ansseau M, Von Frenckell R, Maassen D, et al. Prediction of treatment response to selective antidepressants from clonidine and apomorphine neuroendocrine challenges. In, Briley M, Fillion G, eds. New Concepts in Depression. London, UK: McMillan Press; 1988:269-276.
46. Coote M, Wilkins A, Werstiuk ES, Steiner M. Effects of electroconvulsive therapy and desipramine on neuroendocrine responses to the clonidine challenge test. J Psychiatry Neurosci. 1998;23:172-178.
47. Correa H, Duval F, Mokrani MC, et al. Noradrenergic dysfunction and antidepressant treatment response. Eur Neuropsychopharmacol. 2001;11:163-168.
48. Nemeroff CB. Psychopharmacology of affective disorders in the 21st century. Biol Psychiatry. 1998;44:517-525.
49. Argyropoulos SV, Wilson SJ. Sleep disturbances in depression and the effects of antidepressants. Int Rev Psychiatry. 2005;17:237-245.
50. Modell S, Ising M, Holsboer F, Lauer CJ. The Munich vulnerability study on affective disorders: premorbid polysomnographic profile of affected high-risk probands. Biol Psychiatry. 2005;58:694-699.
51. Hatzinger M, Hemmeter UM, Brand S, Ising M, Holsboer-Trachsler E. Electroencephalographic sleep profiles in treatment course and long-term outcome of major depression: association with DEX/CRH-test response. J Psychiatr Res. 2004;38:453-465.
52. Wilson S, Argyropoulos S. Antidepressants and sleep: a qualitative review of the literature. Drugs. 2005;65:927-947.
53. Salin-Pascual RJ, Galicia-Polo L, Drucker-Colin R. Sleep changes after 4 consecutive days of venlafaxine administration in normal volunteers. J Clin Psychiatry. 1997;58:348-350.
54. 2 receptors. Naunyn-Shmiedeberg's Arch Pharmacol. 2003;367:553-561.
55. 2C Receptors, blokade of which enhances the activity of frontocrotical dopaminergic and adrenergic pathways. JPET. 2003;306:954-964.
56. Guilleminault C. Efficacy of agomelatine versus venlafaxine on subjective sleep of patients with Major Depressive Disorder. Eur Neuropsychopharmacol. 2005;15(suppl 3):S419.
57. Quera Salva MA, Vanier B, Chapotot F, et al. Effect of agomelatine on the sleep EEG in patients with major depressive disorder (MMD). Eur Neuropsychopharmacol. 2005;15(suppl 3):S435.
58. Lam, RW. Sleep disturbances and depression: a challenge for antidepressants. Int Clin Psychopharmacol. 2006;21(suppl 1):S25-S29.
59. Bondy B. Pharmacogenomics in depression and antidepressants. Dialogues Clin Neurosci. 2005;7:223-230.
60. Heils A, Teufel A, Petri S, et al. Allelic variation of human serotonin transporter gene expression. J Neurochem. 1996;66:2621-2624.
61. Caspi A, Sugden K, Moffitt TE, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science. 2003;301:386-389.
62. Wilhelm K, Mitchell PB, Niven H, et al. Life events, first depression onset and the serotonin transporter gene. Br J Psychiatry. 2006;188:210-215.
63. Serretti A, Lilli R, Smeraldi E. Pharmacogenetics in affective disorders. Eur J Pharmacol. 2002;438:117-128.
64. Mancama D, Kerwin RW. Role of pharmacogenomics in individualising treatment with SSRIs. CNS Drugs. 2003;17:143-151.
65. Mrazek DA, Smoller JW, de Leon J. Incorporating pharmacogenetics into clinical practice: Reality of a new tool in psychiatry. CNS Spectr. 2006;11(3, suppl 3):1-13.
66. Binder EB, Holsboer F. Pharmacogenomics and antidepressant drugs. Ann Med. 2006;38:82-94.
67. Hastings RS, Parsey RV, Oquendo MA, Arango V, Mann JJ. Volumetric analysis of the prefrontal cortex, amygdala, and hippocampus in major depression. Neuropsychopharmacology. 2004;29:952-959.
68. Manji HK, Quiroz JA, Sporn J, et al. Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol Psychiatry. 2003;53:707-742.
69. Campbell S, McQueen G. An update on regional brain volume differences associated with mood disorders. Curr Opin Psychiatry. 2006;19:25-33.
70. Iosifescu DV, Renshaw PF, Lyoo IK, et al. Brain white-matter hyperintensities and treatment outcome in major depressive disorder. Br J Psychiatry. 2006;188:180-185.
71. Wu JC, Gillin JC, Buchsbaum MS, Hershey T, Johnson JC, Bunney WE. Effect of sleep deprivation on brain metabolism of depressed patients. Am J Psychiatry. 1992;149:538-543.
72. Ebert D, Feistel H, Barocka A, Kaschka W. Increased limbic flow and total sleep deprivation in major depression with melancholia. 1994;55:101-109.
73. Ebert D, Ebmeier KP. The role of the cingulate gyrus in depression - from functional anatomy to neurochemistry. Biol Psychiatry. 1996;39:1044-1050.
74. Mayberg HS, Brannan SK, Mahurin RK, et al. Cingulate function in depression - a potential predictor of treatment response. NeuroReport. 1997;8:1057-1061.
75. Vlassenko A, Sheline YI, Fischer K, Mintun MA. Cerebral perfusion response to successful treatment of depression with different serotoninergic agents. J Neuropsychiatry Clin Neurosci. 2004;16:360-363.
76. Martin SO, Martin E, Rai SS, Richardson MA, Royall R. Brain blood flow changes in depressed patients treated with interpersonal psychotherapy or venlafaxine hydrochloride: preliminary findings. Arch Gen Psychiatry. 2001;58:641-648.
77. Zobel A, Joe A, Freymann N, Clusmann H, Schramm J, Reinhardt M, Biersack HJ, Maier W, Broich K. Changes in regional cerebral blood flow by therapeutic vagus nerve stimulation in depression: an exploratory approach. Psychiatry Res. 2005;139:165-179.
78. Ezquiaga E, Ayuso Gutierrez JL, Garcia Lopez A. Psychosocial factors and episode number in depression. J Affect Disord. 1987;12:135-138.
79. Mitchell PB, Parker GB, Gladstone GL, Wilhelm K, Austin MP. Severity of stressful life events in first and subsequent episodes of depression: the relevance of depressive subtype. J Affect Disord. 2003;73:245-252.
80. Manji HK, Drevets WC, Charney DS. The cellular neurobiology of depression. Nat Med. 2001;7:541-547.
81. Post, RM. Transduction of psychosocial stress into the neurobiology of recurrent affective disorder. Am J Psychiatry. 1992;149:999-1010.
82. Weiss SR, Post RM. Kindling: separate vs. shared mechanisms in affective disorders and epilepsy. Neuropsychobiology. 1998;38:167-180.
83. Monroe SM, Harkness K L. Life stress, the "kindling" hypothesis, and the recurrence of depression: considerations from a life stress perspective. Psychol Rev. 2005;112:417-445
84. McEwen BS. Protection and damage from acute and chronic stress: allostasis and allostatic overload and relevance to the pathophysiology of psychiatric disorders. Ann N Y Acad Sci. 2004;1032:1-7.
85. O'Connor TM, O'Halloran DJ, Shanahan F. The stress response and the hypothalamic-pituitary-adrenal axis: from molecule to melancholia. Q J Med. 2000;93:323-333.
86. Carrasco GA, Van de Kar LD. Neuroendocrine pharmacology of stress. Eur J Pharmacol. 2003;463:235-272.
87. Tsigos C, Chrousos, GP. Hypothalamic-pituitary-adrenal axis, neuroendocrine factors and stress. J Psychosom Res. 2002;53:865-871.
88. Brown AS, Gershon S. Dopamine and depression. J Neural Transm Gen Sect. 1993;91:75-109.
89. Jackson IM. The thyroid axis and depression. Thyroid. 1998;8:951-956.
90. Anand A, Charney DS. Norepinephrine dysfunction in depression. J Clin Psychiatry. 2000;61:16-24.
91. Duval F, Mokrani MC, Monreal-Ortiz JA, et al. Cortisol hypersecretion in unipolar major depression with melancholic and psychotic features: dopaminergic, noradrenergic and thyroid correlates. Psychoneuroendocrinology. In press.
92. Gary KA, Sevarino KA, Yarbrough GG, Prange AJ Jr, Winokur A. The thyrotropin-releasing hormone (TRH) hypothesis of homeostatic regulation: implications for TRH-based therapeutics. J Pharmacol Exp Ther. 2003;305:410-416.
93. Duval F, Mokrani MC, Bailey P, Correa H, Diep TS, Crocq MA, Macher JP. Thyroid axis activity and serotonin function in major depressive episode. Psychoneuroendocrinology. 1999;24:695-712.
94. Itil TM, Patterson CD, Polvan N, Mehta D, Bergey B. Clinical and CNS effects of oral and i.v. thyrotropin releasing hormone (TRH). Psychopharmacol Bull. 1975;11:29-30.
95. Marangell LB, George MS, Callahan AM, et al. Effects of intrathecal thyrotropin-releasing hormone (protirelin) in refractory depressed patients. Arch Gen Psychiatry. 1997;54:214-222.
96. Duman RS. Neural plasticity: consequences of stress and actions of antidepressant treatment. Dialogues Clin Neurosci. 2004;6:157-169.
97. MacQueen GM, Campbell S, McEwen BS, et al. Course of illness, hippocampal function, and hippocampal volume in major depression. Proc Natl Acad Sci U S A. 2003;100:1387-1392.
98. Sheline YI, Sanghavi M, Mintun MA, Gado MH. Depression duration but not age predicts hippocampal volume loss in medically healthy women with recurrent major depression. J Neurosci. 1999;19:5034-5043.
99. Nemeroff CB, Vale WW. The neurobiology of depression: inroads to treatment and new drug discovery. J Clin Psychiatry. 2005;66(suppl 7):5-13.
100. Souêtre E, Salvati E, Wehr TA, Sack DA, Krebs B, Darcourt G. Twenty-four hour profile of body temperature and plasma TSH in bipolar patients during depression and during remission and in normal controls subjects. Am J Psychiatry. 1988;139:282-286.
101. Wirz-Justice A. Biological rhythms in mood disorders. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: the Fourth Generation of Progress. New York, NY: Raven Press; 1995:999-1017.
102. Krauchi K, Cajochen C, Mori D, Graw P, Wirz-Justice A. Early evening melatonin and S-20098 advance circadian phase and nocturnal regulation of core body temperature. Am J Physiol. 1997;272:R1178-R88.
103. Leproult R, Van Onderbergen A, L'hermite-Baleriaux M, et al. Phase-shifts of 24-h rhythms of hormonal release and body temperature following early evening administration of the melatonin agonist agomelatine in healthy older men. Clin Endocrinol. 2005;63:298-304.
104. 2c antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol. 2002;17:239-247.
105. Kennedy SH, Emsley R. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur Neuropsychopharmacol. 2006;16:93-100.
106. Den Boer JA Bosker FJ, Meesters Y. Clinical efficacy of agomelatine in depression: the evidence. Int Clin Psychopharmacol. 2006;21(suppl 1):S21-S24.
107. Schulz P, Berney P. Clinician's predictors of patient response to psychotropic medication. Dialogues Clin Neurosci. 2004;6:105-111.
108. Wirz-Justice A. Biological rhythm disturbances in mood disorders. Int Clin Psychopharmacol. 2006;21:S11-S15.
109. Krzystanek M, Krupka-Matuszczyk I, Bargiel-Matusiewicz K. Observations of toleranc of bright light treatment in psychiatry. Psychiatr Pol. 2005;39:449-458.
110. Frank E, Novick D, Kupfer DJ. Antidepressants and psychotherapy: a clinical research review. Dialogues Clin Neurosci. 2005;7:263-272.
111. Aberg-Wistedt A. A double-blind study of zimelidine, a serotonin uptake inhibitor, and desipramine, a noradrenaline uptake inhibitor, in endogenous depression. 1: Clinical findings. Acta Psychiatr Scand. 1982;66:129-138.
112. Humble M. Noradrenaline and serotonin reuptake inhibition as clinical principles: a review of antidepressant efficacy. Acta Psychiatr Scand. 2000;402(suppl):28-36.
113. Eriksson E. Antidepressant drugs: does it matter if they inhibit the reuptake of noradrenaline or serotonin? Acta Psychiatr Scand. 2000;402(suppl):12-17.
114. Eriksson E, Hedberg MA, Andersch B, et al. The serotonin reuptake inhibitor paroxetine is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual syndrome. Neuropsychopharmacology. 1995;12:167-176.
115. Aberg-Wistedt A. Comparison between zimelidine and desipramine inendogenous depression: a cross-over study. Acta Psychiatr Scand. 1982;66:129-213.
116. Thase ME, Rush AJ. Treatment-resistant depression. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: the Fourth Generation of Progress. New York, NY: Raven Press; 1995:1081-1097.
117. Spigset O, Martensson B. Fortnightly review: drug treatment of depression. BMJ. 1999;318:1188-1191.
118. Anderson IM, Nutt DJ, Deakin JF. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. British Association for Psychopharmacology. J Psychopharmacol. 2000;14:3-20.
119. Anderson IM. SSRIs versus tricyclic antidepressants in depressed inpatients: a meta analysis of efficacy and tolerability. Depression Anxiety. 1998;7 (suppl 1):11-17.
120. Danish University Antidepressant Group (DUAG). Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. Psychopharmacology. 1986;90:131-138.
121. Danish University Antidepressant Group (DUAG). Paroxetine: a selective serotonin reuptake inhibitor showing a better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affective Disord. 1990;18:289-299.
122. Danish University Antidepressant Group (DUAG). Moclobemide: a reversible MAO-A inhibitor showing weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affective Disord. 1993;28:105-116.
123. Trindade E, Menon D. Selective Serotonin Reuptake Inhibitors (SSRIs) for Major Depression. Part 1: Evaluation of the Clinical Literature. Ottawa, Canada: Canadian Coordinating Office for Health Technology Assessment; 1997(Report 3E.)
124. Kasper S, Bech P, de Jonghe F, et al. Treatment of unipolar major depression: algorithms for pharmacotherapy. Int J Psychatry Clin Pract. 1997;1:55-57.
125. Baumann P, Ulrich S, Eckermann G, et al. Arbeitsgemeinschaft fur Neuropsychopharmakologie und Pharmakopsyhiatrie - Therapeutic Drug Monitoring Group. The AGNP-TDM Expert Group Consensus Guidelines: focus on therapeutic monitoring of antidepressants. Dialogues Clin Neurosci. 2005;7:231-247.
126. Scordo MG, Spina E, Dahl ML, Gatti G, Perucca E. Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine. Basic Clin Pharmacol Toxicol. 2005;97:296-301.
127. Berney P. Dose-response relationship of recent antidepressants in the short-term treatment of depression. Dialogues Clin Neurosci. 2005;7:249-262.
128. Fava M, Rosenbaum JF, McGrath PJ, Stewart JW, Amsterdam JD, Quitkin FM. Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study. Am J Psychiatry. 1994;151:1372-1374.
129. Muth FA, Moyer JA, Haskins JT, Andree TH, Husbands GEM. Biochemical, neurophysiological and behavioral effects of WY 45,233, its enantiomers, and other identified metabolites of the antidepressant venlafaxine. Drug Dev Res. 1991;23:191-199.
130. Rudolph RL, Fabre LF, Feighner JP, Rickels K, Entsuah R, Derivan AT. A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression. J Clin Psychiatry. 1998;59:116-122.
131. Mbaya P. Safety and efficacy of high dose of venlafaxine XL in treatment resistant major depression. Hum Psychopharmacol Clin Exp. 2002;17:335-339.
132. Abuzzahab FS, Kayongo MN. High doses of venlafaxine in treatment-resistant depression. Bipolar Disord. 2004;6(suppl 1):35 (Abstract).
133. Rouillon F, Gorwood P, The use of lithium to augment antidepressant medication. J Clin Psychiatry. 1998;59(suppl 5):32-39.
134. DeBattista C, Lembke A. Update on augmentation of antidepressant response in resistant depression. Curr Psychiatry Rep. 2005;7:435-440.
135. Blier P, Szabo ST. Potential mechanisms of action of atypical antipsy chotic medications in treatment-resistant depression and anxiety. J Clin Psychiatry. 2005;66(suppl 8):30-40.
136. Nemeroff CB. Use of atypical antipsychotics in refractory depression and anxiety. J Clin Psychiatry. 2005;66(suppl 8):13-21.
137. Simon JS, Nemeroff CB. Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder. J Clin Psychiatry. 2005;66:1216-1220.
138. Holmes VF. Related Medical use of psychostimulants: an overview. Int J Psychiatr Med. 1995;25:1-19.
139. Menza MA, Kaufman KR, Castellanos A. Modafinil augmentation of antidepressant treatment in depression. J Clin Psychiatry. 2000;61:378-381.
140. O'Connor MK, Knapp R, Husain M, et al. The influence of age on the response of major depression to electroconvulsive therapy: a C.O.R.E. Report. Am J Geriatr Psychiatry. 2001;9:382-390.
141. Carpenter LL. Neurostimulation in resistant depression. J Psychopharmacol. 2006;20:35-40.
142. Wirz-Justice A, Benedetti F, Berger M, et al. Chronotherapeutics (light and wake therapy) in affective disorders. Psychol Med. 2005;35:939-944.
143. Reus VI, Wolkowitz OM. Antiglucocorticoid drugs in the treatment of depression. Expert Opin Investig Drugs. 2001;10:1789-1796.
144. Rothschild AJ. Challenges in the treatment of depression with psychotic features. Biol Psychiatry. 2003;53:680-690.
145. Flores BH, Kenne H, Keller J, Solvason HB, Schatzberg AF. Clinical and biological effects of mifepristone treatment for psychotic depression. Neuropsychopharmacology. 2006;31:628-636.
146. Holsboer F. The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety. J Psychiatr Res. 1999;33:181-214.
147. Held K, Kunzel H, Ising M, et al. Treatment with the CRH1-receptor- antagonist R121919 improves sleep-EEG in patients with depression. J Psychiatr Res. 2004;38:129-136.